Tag: Dr. Clemen Chiang

Venture growth investor in Healthcare, Longitude Venture Partners Iv investor portfolio, healthcare Longitude Venture Partners

Details On Longitude Venture Growth Investor in Healthcare

Longitude Venture Partners Iv investor portfolio expands its Venture growth investor in Healthcare. Know details on healthcare Longitude Venture Partners!

Longitude Capital Expands Biotechnology Practice With Matthew Young

– Young held senior leadership positions at GRAIL and Jazz Pharmaceuticals after successful 20-year investment banking career at Barclays, Citigroup, Lehman Brothers, and Merrill Lynch –

Longitude Capital, a leading healthcare venture capital firm focused on venture growth investments in biotechnology, medical technology, and health solutions, announced that veteran life sciences executive Matthew Young has joined the firm as Managing Director. Mr. Young joins Longitude Capital after almost a decade in leadership positions at GRAIL and Jazz Pharmaceuticals, and 20 years in investment banking.

“Matt’s corporate development, financial, and C-suite operating experience spans life science businesses across multiple sectors and stages, all of which will contribute to our investment decision-making and to supporting our portfolio companies with strategic counsel,” said Longitude Managing Director and Co-founder Patrick Enright. “We are extremely excited to have Matt join our team as we continue to invest in innovative biotechnology companies that, like us, seek to transform the healthcare industry.”

Prior to joining Longitude Capital, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to JAZZ, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies. Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the audit committee of CytomX Therapeutics (CTMX) as well as a board member of Alpha-9 Therapeutics.

“I have focused my career on supporting companies across the healthcare continuum that strive to improve patients’ lives by building sustainable businesses that meaningfully improve the standard of care and outcomes. I’m excited to help shape Longitude’s biotechnology practice in its pursuit and advancement of critical therapeutic and diagnostic solutions that will further our shared mission,” said Mr. Young.

Longitude Capital also announced a cadre of new additions to its biotechnology practice in 2022 in support of the Firm’s continued growth in this core sector:

• Brahma Kumar, MD, PhD – Dr. Kumar is a Vice President on the Biotechnology team and is based in the Greenwich and Boston offices. Prior to joining the Firm, Dr. Kumar was an Engagement Manager at McKinsey & Co., where he focused on R&D strategy for biopharmaceutical clients. Dr. Kumar holds a PhD in Immunology, an MD from Columbia University, and a BA in Economics from Johns Hopkins University.
• Cindy Wang, PhD – Dr. Wang is a Vice President on the Biotechnology team and is based in the Menlo Park office. Prior to joining the Firm, Dr. Wang most recently served as a Senior Director of Strategy & Corporate Development at Dascena, a Longitude portfolio company. Prior to Dascena, Dr. Wang was an Engagement Manager at L.E.K. Consulting, where she consulted for life sciences companies on drug development, and commercial and portfolio strategy. Dr. Wang holds a PhD in Molecular and Cell Biology from the University of California, Berkeley, and a BA in Chemical and Physical Biology from Harvard University.
• Zack Ely, PhD – Dr. Ely is a Senior Associate on the Biotechnology team and is based in the Boston office. Prior to joining the Firm full-time, Dr. Ely was a Research Fellow under the Longitude Research Network (LRN), the Firm’s dedicated arm for identifying cutting-edge innovations within sectors, therapeutic areas, or technologies of interest. Dr. Ely holds a PhD in Biology from the Massachusetts Institute of Technology, where he specialized in genome engineering and cancer immunology. Dr. Ely also holds a BA in Molecular and Cellular Biology from Vanderbilt University.

About Longitude Capital

Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors’ new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*

Longitude Capital is an expert in generating venture growth investments in biotechnology as well as medical advances firms that helps to develop quality of life, lower system expenses, and/or enhance medical results. The foundation of the firm’s growth strategy is the development of a well-balanced portfolio of diagnostic and therapeutic and commercial-stage businesses with medically de-risked assets, favorable valuations in relation to risk profile, and alluring future profits within 3 to 5 years of original investment. Longitude Capital also makes use of a range of investment structures, such as standard venture capital, capital spin-outs, recapitalizations, PIPEs, open market transactions, royalties, and equity-linked instruments.

Creating a balanced portfolio of clinical-stage as well as commercial-stage businesses with clinically de-risked products, advantageous valuations compared to risk profile, and alluring predicted returns within three to five years after initial investment is the foundation of their venture growth plan.

Investment At Longitudinal Capital

Longitude Capital uses its extensive network of contacts in the sector to find fresh investment opportunities.

or by conducting in-depth topic research into new therapeutic sub-sectors or business segments. In addition to typical venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity and equity-linked instruments are among the investment formats they use.

After a first investment, They closely collaborate with investee companies and drug cartel partner organizations to create and carry out strategic plans, accomplish crucial operational goals, assemble world-class teams, raise money, and pursue liquidity possibilities in a way that maximizes returns to important stakeholders.

Longitude Capital, a VC that was founded in 2006, seemed to be the company investment description. To be more precise, the facility was based in the United States in North America. Menlo Park is home to defined VC’s premier regional office.

Health Diagnostics and Therapeutics are two of the industries with the most lucrative fund investment opportunities. In addition, a business must be 6 to 10 years old to qualify for a fund investment. Alphaeon, CardioDx, and SutroVax are a few of the fund’s most well-known portfolio startups. The fund has a specific preference for a number of portfolio startup entrepreneurs. Startups with five or more founders have a low chance of receiving funding. The country in which the fund was founded and the site of its various assets, the United States, are complementary.

The fund typically makes investments in rounds with 5–6 participants. Startups are frequently funded by Kleiner Perkins, The Carlyle Group, and TVM Capital despite Longitude Capital. The important sponsors supporting the fund’s investment in a single round are Kleiner Perkins, OrbiMed, and RA Capital Management. Kleiner Perkins, Rock Springs Capital, and RA Capital Management frequently get funds in the subsequent rounds.

Patrick Enright and Marc Galletti started the present fund. In Their information, They also computed 7 important employees.

Deals between $10 and $50 million are frequently done for funds. In contrast to the other firms, Longitude Capital operates on lead investments that are 1 percentage point lower on average. According to real fund outcomes, this VC commits to exiting companies 23 percentage points greater frequently than other corporations. 2018 saw a rise in the number of fund departures. The typical startup valuation for an investment from Longitude Capital is between $500 million and $1 billion. 2015 saw a surge in fund activity. Despite this, the fund was active in 2019. The fund consistently participates in two to six deals each year.

Associate Partners At Longitude Capital

The founders of Longitude Capital have been collaborating on investments since 2002. Their team has worked together on more than 70 additional investment and 150 follow-on investment opportunities in the biotechnology, medical advances, and health solutions industries. They have more than 150 years of combined investing expertise in the life sciences industry. Their headquarters are in Menlo Park, California, and They also have operations in Greenwich, Connecticut, and Boston, Massachusetts.

Putting money towards medical innovation

Longitude Capital participates in biotechnology, medical advances, and health solutions businesses that aim to boost standard of living, lower system costs, and/or improve treatment results. They are committed to assisting management teams in achieving technological, clinical, and economic milestones for start-ups and growth equity investors in order to generate value and provide enticing returns to the limited partners.

Major Investment By Longitudinal Capital – A clinical phase radiopharmaceutical business based in Vancouver, Canada and Boston, Massachusetts, Alpha-9 Theranostics, received $75M in Series B funding

In addition to Frazier Life Sciences, Samsara BioCapital, Quark Venture, Longitude Capital, and BVF Partners, Nextech Invest served as the round’s lead investor. Nextech Invest’s Melissa McCracken, Ph.D., Partner Senior Partner at Frazier Life Sciences and M.B.A. Patrick Heron Together with Darcy Mootz, Ph.D., Location Head at Amunix, a Sanofi Company (Chief Commercial Officer prior to selling), who will participate as a Board advisor, Cory Freedland, Ph.D., Partner at Samsara BioCapital, and Matthew Young, M.B.A., Managing Partner at Longitude Capital will participate the Alpha-9 Board of Directors.

The company plans to utilize the money to grow its early-stage initiatives while advancing five of its programmes into the clinic within the next 2 years.

Alpha-9 Theranostics was established in 2019 by François Bénard, M.D., Kuo-Shyan Lin, Ph.D., as well as David Perrin, Ph.D., investigators from BC Cancer and also the University of British Columbia with extensive experience in modifying peptides and small molecules to formulate new radiopharmaceuticals. These radiopharmaceuticals have the ability to significantly enhance the treatment of cancer patients. The company is at the forefront of developing custom radiopharmaceuticals that are designed to selectively administer radiation to tumor areas while minimizing off-target effects by utilizing proprietary technology and expertise. With a methodical approach to molecule design, Alpha-9 is developing a pipeline of innovative radiopharmaceuticals that has the potential to expand into a number of confirmed oncology targets.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors’ new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*

Kathy P. Vrabeck is the Beachbody Company’s chief operating officer.

What is the net worth of Kathy P. Vrabeck?

Kathy P. Vrabeck, the CHIEF OPERATING OFFICER at Beachbody Company, Inc., is thought to currently have a net worth of roughly $33.89 million. Approximately 868,352 shares of Beachbody Company, Inc. common stock are held by Kathy P. Vrabeck. At Beachbody Company, Inc., Kathy P. Vrabeck has sold products with an estimated worth of $0 during the last 8 months.

How did Kathy P. Vrabeck trade insiders in the past?

On May 20, 2022, Kathy P. Vrabeck placed a purchase order for 468,418 units totaling more than $499.99K. Kathy P. Vrabeck has worked at Beachbody Company, Inc. for 8 months and has got a handful of around 4 transactions. Kathy P. Vrabeck often trades in May, with 2022 being her busiest year. A buy order for 250,000 units, valued at around $175.25K on December 1, 2022, was the most latest transaction.

Over the past 19 years, Ms. Vrabeck has sold GME stock for over $1,609,300 while owning over 1,316 shares of Gamestop stock valued at over $813,044. She also receives $277,727 in salary from Gamestop as Executive Chairman of the Board.

Insider trading on Ms. Vrabeck’s SEC Form 4 for GME shares

Kathy has conducted over 16 trades of the Gamestop shares since 2003, based on the Form 4 lodged with the SEC. On October 30, 2022, she just recently acquired 1,316 GME stock units worth $29,807 in total.

Her largest transaction to date was the exercise of 372,498 shares of Gamestop stock for a total value of about $2,730,410 on 1 June 2005. From 2003, Kathy has traded 29,909 units per 250 days on average. She still had at least 35,896 shares of Gamestop stock as at 30 October 2022.

Kathy P Vrabeck Form 4 Trading Tracker

In total, Kathy P. Vrabeck has made 2 trades in GameStop Corp. (GME) during the past 5 years, comprising 1 buy and 1 sell, as per SEC Form 4 filings. The most recent transaction involving GameStop Corp. involved Kathy P. Vrabeck selling 200,000 shares for almost $1 million on January 13, 2021.

Kathy P. Vrabeck has had 0 trades in Activision Blizzard Inc. (ATVI) during the last 5 years, as per SEC Form 4 filings. The most latest transaction involving Activision Blizzard Inc. saw Kathy P. Vrabeck selling 993,303 shares for almost $6 million on June 1, 2005.

The Beachbody Co Inc (BODY) has seen Kathy P Vrabeck execute a total of 2 trades over the last 5 years, involving 2 purchases and 0 sells, as per SEC Form 4 filings. The Beachbody Co Inc’s most recent transaction is the purchase of 250,000 units on November 30, 2022, for a price of about $175,000 for Kathy P Vrabeck.

Biography of Kathy Vrabeck

As of June 2020, Kathy P. Vrabeck will serve as the company’s executive chairman of the board. She works closely with customers in the customer and technology industries as a Senior Client Partner at Korn Ferry International’s Los Angeles branch, a worldwide people and organisational advising agency. She worked as a Partner at executive search company Heidrick & Struggles International, Inc. (“Heidrick & Struggles”) from October 2014 to October 2015, in which she held the positions of Global Sector Leader of their Media, Entertainment and Digital practise and Companion of the Los Angeles office.

Ms. Vrabeck worked for media group Legendary Entertainment from March 2009 to March 2011 where she held the position of President, Legendary Digital and was in charge of developing, managing, and distributing digital entertainment, with a concentration on video games, all over current and future-generation platforms. She joined Heidrick & Struggles in July 2011 from there.

Ms. Vrabeck worked for Electronic Arts, Inc. (“EA”) from May 2007 to November 2008 as President, EA Casual Entertainment, where she oversaw EA’s initiatives in the fastest-growing areas of the video game industry mobile, online, networking sites, and international media sales. From August 1999 to April 2006, Ms. Vrabeck worked for the video game publisher Activision, Inc. (also known as “Activision”), in which she held the position of President, Activision Publishing. In this role, she was in charge of Activision’s product design, global brand management, and publishing activities. Previously in her career, Ms. Vrabeck worked for ConAgra, The Pillsbury Company, Quaker Oats, and Eli Lilly & Company in a variety of marketing, sales, and financial roles.  Presently, Ms. Vrabeck is a trustee at DePauw University.

Trading by Insiders at Gamestop

Insiders at Gamestop have purchased 1,492,293 shares valued at $31,136,404 and sold over $72,339,456 value of the company’s stock over the past 17 years. James J. Kim, Leonard Riggio, and Ryan R.C. Ventures L.L.C. Cohen are some of the most active insiders traders. Every 43 days on average, Gamestop’s individual directors and executives transact stock, with the average transaction valued at $1,169,307. Alain Attal made the most popular stock transaction on March 24, 2022, exchanging 1,500 units of GME stock, which is worth approximately $194,865.

Kathy Vrabeck Insider Ownership Reports

According to ownership data from SEC filings, Kathy P. Vrabeck, the reported owner, holds a total of seven businesses, comprising GameStop Corp. (GME), Electronic Arts Inc. (EA), and AVP Inc. (AVPI).

K. P. Vrabeck Latest holdings

Presently, Kathy P. Vrabeck holds a total of 3 stocks. As of January 13, 2021, Kathy P Vrabeck owned 318,148 units of GameStop Corp (GME), with a market price of $5 million and a weighted of 64.88%, between these stocks. As of June 1, 2005, Kathy P Vrabeck owned 30,362 units of Activision Blizzard Inc (ATVI), valued at $2 million and weighted at 29.19%. Kathy P Vrabeck also owns 868,352 shares of The Beachbody Co Inc (BODY) as of November 30, 2022, with a value of $476,117 and a weighting of 5.93%.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors’ new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*

Li Ka Shing only earns a few hundred million since he puts in millions, while Buffett earns a few billions with his company with just 200% since he invested billions.

However, when we make tiny bets as individual investors, we want to go for a quick and higher proportion. The latest quarter saw changes to Berkshire Hathaway’s bank holdings, a significant gamble on energy equities, and an increase in Apple shareholding. Let’s take a deeper look at those 3 crucial actions.

The US stock holdings of Warren Buffett’s Berkshire Hathaway as of June 30 were disclosed in a quarterly portfolio report posted on Monday. The illustrious investor’s conglomerate increased its largest stake throughout that time, increased its energy bets, and adjusted its financial bets.

A Further Apple Bite

In June, Apple stock traded as low as $129, roughly 30% below its record of $183 at the beginning of the year. Given that they purchased approximately 4 million extra units of the iPhone manufacturer in the second half, increasing their holding to 895 million units or 5.6%, Buffett and his colleagues undoubtedly thought the stock was a bargain.

The US stock holdings of Warren Buffett’s Berkshire Hathaway as of June 30 were disclosed in a quarterly strategy report posted on Monday. The illustrious investor’s conglomerate increased its largest stake throughout that time, increased its energy bets, and adjusted its financial bets.

At $159.1 billion since about Q1 2022, Apple, the company that makes iPhones, is unquestionably Berkshire Hathaway’s biggest stock position, making up over 41% of its stock portfolio and 5.5% of Apple’s shareholdings.

For less than $35 million, Berkshire Hathaway purchased the share between 2016 and 2019. Apple replaced Wells Fargo as Berkshire Hathaway’s top stock in early 2018.

Apple shares fell as little as $129 in June, over 30% below their record of $183 at the beginning of the year. Given that they purchased approximately 4 million extra shares of the iPhone manufacturer in the second quarter, increasing their holding to 895 million shares or 5.6%, Buffett and his colleagues undoubtedly thought the stock was a bargain.

Apple is Berkshire’s largest stake, making up more than 40% of the $300 billion stock portfolio of the corporation. Due to the 27% increase in Apple’s stock price during the past six weeks, the position’s rate has increased from $122 billion to $155 billion.

Apple has been hailed by Buffett as a “family jewel” and “possibly the best corporation” he is aware of in recent years. In just a few short years, Berkshire has over quadrupled his paper wealth. Between 2016 and 2018, Berkshire invested about $36 billion in increasing its controlling interest in the tech giant.

More Exercising, More Profits

This year, Berkshire invested more than $25 billion in Chevron as well as Occidental Petroleum. The frantic purchase indicates Buffett and his team are optimistic on fossil fuels and eager to profit on this year’s spike in energy prices, which has been spurred by Russia’s invasion of Ukraine, which has disrupted the world’s energy supplies.

After increasing its stake in the oil giant from 38 million units to 158 in the first quarter, Buffett’s company disclosed that it purchased around 2.3 million Chevron shares in the most recent quarter. The value of the expanded holding has increased to around $25 billion as a result of the 31% increase in Chevron’s share price this year.

Just at the end of June, Berkshire included 159 million Occidental stocks in its holdings. According to records, Buffett’s business has now boosted its holding to 188 million shares, providing it a 20% holding in the oil and gas developer and producer.

It’s important to note that Berkshire also has warrants allowing it to purchase 83.9 million ordinary stock for a fixed price of $5 billion and holds preferred shares in Occidental valued at $10 billion. It got both in return for funding Occidental’s 2019 acquisition of Anadarko Petroleum.

Investing in Banks

Over the previous two years, Berkshire has updated its bank holdings. It increased its enormous holding in Bank of America, sold off substantial positions in JPMorgan, Wells Fargo, and Goldman Sachs, and built a nearly $3 billion holding in Citigroup in the first quarter.

The previous quarter, Buffett and his staff made additional adjustments to their financial wagers. At the current market price of the bank, they have then tripled their stakes in Ally Financial to 30 million shares, which are now worth $1.1 billion. On either hand, they reduced their bet on US Bancorp by 5% to approximately 120 million shares, which are now worth $5.9 billion..

The Bottom Line

At Berkshire Hathaway’s annual shareholder conference on Saturday, billionaire investor Warren Buffett disclosed that his company increased its holding of Apple over the first quarter.

When discussing the importance of stock buybacks, Buffett stated, “We did buy a bit more Apple during the first quarter, and Apple purchased out a few of the other stockholders. He didn’t say by how much, but in mid-May Berkshire would give a report on its stock holdings as of March 30.

Just at the end of December, Berkshire possessed 908 million Apple shares, totaling $161 billion. According to its first-quarter profits, its Apple share was valued $159 billion at the end of March. That occurred in spite of the stock declining by 2% last quarter, indicating a minor strengthening of its position.

In Berkshire’s investment portfolio, which was valued at $391 billion at the close of March, Apple is perhaps the most lucrative holding. With a stake of over than 5%, Berkshire is Apple’s biggest individual shareholder.

During the meeting, Buffett praised the firm’s stock buybacks, pointing out that they increase Berkshire’s ownership of the firm at no additional cost to Berkshire. He has earlier lauded Apple as among the best businesses he actually understands, commended Apple CEO Tim Cook as a great manager, and represented it as one of Berkshire’s “four giants” in his yearly letter, in addition to the insurance industry, the BNSF Railway, and Berkshire Hathaway Energy.

Kingsoft Corporation limited works as an Investment holding company in China. It provides services for the development and distribution of applications, protection, and multimedia software. The business of popular game services, smartphone applications, and online games is provided by the company. It also operates a distribution network for these types of games. Kingsoft also offers office software services and products, such as design, sales, and marketing, as well as research and development. The business offers online marketing, network security, and value-added services for the internet in addition to game licensing. It runs businesses in China, Hong Kong, and the Cayman Islands. Beijing, China serves as the home base of the Kingsoft Corporation.

Performance Evaluation

• The most recent full year of revenue for Kingsoft is $8.105 billion.
• The average annual revenue for Kingsoft’s financial year ending in December 2017 through 2021 was HK$6.459 billion.
• From the fiscal years that ended in December 2017 through 2021, Kingsoft generated a median revenue of HK$ 6.644 billion.
• The peak month for Kingsoft’s revenue over the previous five years was September 2022, when it reached HK$ 8.105 billion.
• Kingsoft’s revenue fell to HK$ 4.892 billion in December 2019, which was a five-year low.

2019 had a decline in Kingsoft’s revenue (HK$ 4.892 billion, -27.2%) while 2017 saw an increase (HK$ 6.221 billion, +45.3%), 2018 saw a rise (HK$ 6.724 billion, +8.1%), 2020 saw a rise (HK$ 6.644 billion, +35.8%), and 2021 saw a rise (HK$ 7.817 billion, +17.7%).

Accounting Statements

Over 23 million businesses worldwide have their private financial information gathered by Dun & Bradstreet.

Financial information in US dollars as of December 31, 2021 (12-month period).

2021 ANNUAL SALES $996.62 USD

The HKG:3888 stock of Kingsoft Corporation Limited has recently exhibited weakness, but the company’s financial outlook appears promising.

Is the market incorrect?

When you consider Kingsoft’s (HKG:3888) recent results and the stock’s 31% decrease over the last three months, it is difficult to be optimistic. Although the company’s fundamentals appear to be solid, long-term financials typically correlate with future changes in market price. We made the choice to concentrate on Kingsoft’s ROE in this article.

A company’s ability to manage and increase its value is measured by its return on equity, or ROE. It is a profitability ratio, which means it calculates the percentage of return on the money invested by the shareholders of the company.

View the latest insider activities of Kingsoft at Race to 100 on Spiking.

How Is Return on Equity Calculated?

The return on equity formula is as follows:

Net profit (from ongoing operations) minus shareholders’ equity equals return on equity.

According to the aforementioned formula, Kingsoft’s ROE is 2.9% = CN839m CN29b (Based on the trailing twelve months to June 2022).

A company’s earnings from the previous year are referred to as the “return.” This implies that the corporation makes a profit of $0.03 for every HK dollar invested by a shareholder.

Why Is ROE Vital For Growing Earnings?

As of now, we know that ROE is a gauge of a business’s profitability. We can then evaluate a company’s prospects for earnings growth based on how well and what proportion of these gains it reinvests, or “preserves.” Assuming all other factors remain constant, a company’s growth rate will be stronger compared to businesses that don’t necessarily exhibit these traits, the higher its ROE and profit retention.

Earnings Growth for Kingsoft including 2.9% ROE

You’ll notice that Kingsoft’s ROE appears to be somewhat lacking. Furthermore, the company’s ROE is completely ordinary even when compared to the corresponding average of 8.3%. Although, Kingsoft’s modest 6.7% net income rise over the last five years is unquestionably a plus. We believe that there might be additional elements at work here. For example, the business is managed well or has a lower payout ratio.

The next step was to compare Kingsoft’s net income growth to that of the industry. We were shocked to discover that Kingsoft’s growth was less than the 30% average growth of the sector during the same time period.

When valuing a stock, earnings growth is a crucial factor to take into account. Investors then need to examine whether or not the anticipated profits growth—or lack thereof—has already been factored into the share price. They can then use this to evaluate if the stock is set up for a promising or gloomy future. Is Kingsoft valued properly in comparison to other businesses?

Is Kingsoft Successfully Using Retained Earnings?

In Kingsoft’s case, its modest 3 median payout ratio of 22% (or a retention ratio of 78%), which shows that the company is investing the majority of its profits to build its business, can likely be used to explain its excellent earnings growth.

Moreover, Kingsoft has paid a dividend for at more than ten years, demonstrating the company’s commitment to returning profits to shareholders. Our most recent data from analysts indicates that the company’s anticipated future payout ratio over the following three years will be around 22%. However, despite no expected change in its payout ratio, Kingsoft’s ROE is forecast to increase to 4.5%.

In conclusion, we believe that Kingsoft has a number of advantages to take into account. Specifically, the fact that it retained the majority of its income, which helped it achieve decent earnings growth. Investors may not, though, be gaining anything from all that reinvestment after all given the low ROE. In light of this, the most recent analyst estimates indicate that the company’s earnings will keep growing. Check out this visualization of analyst estimates for the company to learn more about the most recent expectations for the company.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors’ new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*

A venture capital firm called Bios Partners seeks for and develops advanced biotech in underserved and untapped areas in the United States.

Bios Equity Partners II, L.P. Reports on Insider Ownership

According to ownership reports from SEC filings, Lantern Pharma Inc (LTRN), Cognition Therapeutics Inc (CGTX), and IN8bio Inc (INAB) are the three firms that Bios Equity Partners Ii, Lp is the reporting owner of.

What is Lantern Pharma Inc?

A biotechnology business in the clinical stages is Lantern Pharma Inc. Its main goal is to speed up the drug formulation process while also identifying the patients who will profit from targeted oncology therapy by utilising artificial intelligence (A.I. ), machine learning, and genetic data. Four approved drugs and an Antibody Drug Conjugate (ADC) programme targeting eight therapeutic targets are both part of the company’s development pipeline. Its artificial intelligence (AI) platform, RADR, utilises big data analytics and machine learning to quickly uncover biologically active genomic petitions correlated to drug action and then recognise the cancer patients we assume may profit most from our substances. RADR contains over 18 billion data points.

Who is Lantern Pharma Inc.’s top executives?

Lantern Pharma Inc. is 10% owned by Bios Equity Partners II, Lp. Fletcher Aaron G.l., who owns 10% of Lantern Pharma Inc., as well as Bios Capital Management, Lp and Bios Advisors Gp, Llc, each own 10% of the company.

Lantern Pharma Inc (LTRN) Insider Trades Summary

Bios Equity Partners Ii, Lp has not engaged in any insider trading in Lantern Pharma Inc. across the past 18 months (LTRN). A net sell of 356,445 units by Bios Fund I, Lp and a net selling of 356,445 units by Leslie W. Kreis are two further notable insider transactions involving Lantern Pharma Inc (LTRN).

In conclusion, insiders traded 700,000 shares of Lantern Pharma Inc (LTRN) over the course of the last three months while also purchasing 0 shares, resulting in a net sell of 700,000 shares. Insiders released 712,890 shares of Lantern Pharma Inc (LTRN) over the course of the previous 18 months while acquiring 0 shares, for a net sell of 712,890 shares.

The Insider Trading Tracker table contains the complete history of insider trading for Lantern Pharma Inc (LTRN).

Current Portfolio Companies

• A commercial-stage medical device startup, 410 Medical is committed to creating cutting-edge devices that help front-line healthcare professionals offer better care for very ill patients.
• A medical device firm called Abilitech Medical develops cutting-edge products that enable persons with upper-limb neuromuscular disorders to function on their own.
• A clinical-stage pharmaceutical business called Actuate is dedicated to the creation and marketing of cutting-edge treatments for serious inflammatory and cancerous conditions.
• Azitra is a clinical-stage medical dermatological startup that uses cutting-edge genetic engineering and the power of the microbiome to heal skin diseases.
• Cognition Therapeutics (NASDAQ: CGTX) is a clinical-stage biotechnology firm with a portfolio of disease-modifying specific molecular therapeutic candidates that is focused on synapse health and repair in neurodegenerative illnesses.
• The Novartis business Encore Vision is in the trial stages of researching innovative small molecule treatments for the applied topically of presbyopia, a disorder in which vision deteriorates with age.
• A medical business called i-Lumen Scientific, Inc. is creating a transpalpebral microcurrent electrotherapy tool of the future that is non-invasive and intended to treat people with visual field loss brought on by retinal degeneration.
• The goal of Immune System Programming (ISPTM), a ground-breaking technology platform developed by Immusoft Corporation (immusoft.com), is to treat diseases. ISPTM modifies a patient’s B cells and directs the cells to produce gene-encoded medications (biologics) for rare genetic diseases.
• A clinical-stage immune-oncology firm called IN8bio (NASDAQ: INAB) is dedicated to provide an innovative, over-the-counter cell therapy to treat cancer.
• A clinical-stage biopharmaceutical business called Lantern Pharma (NASDAQ: LTRN) innovates the repurposing, revival, and advancement of precision therapies in oncology. In order to identify patients who are more likely to react to our portfolio of cancer therapies, Lantern uses advancements in machine learning, genetics, and artificial intelligence.
• Lung Therapeutics is a biopharmaceutical firm in the early stages that was established to take advantage of decades of groundbreaking research in orphan lung areas where there are unfulfilled medical needs.
• ONL Therapeutics is a firm in the trial stages with a revolutionary strategy for maintaining eyesight and reversing vision loss brought on by a variety of retinal diseases. The business is developing ground-breaking technology that will stop the activation of the Fas pathway from killing important retinal cells.
• A vast pipeline of uncommon hereditary blindness disorders are being addressed by Opus Genetics, a preclinical startup that is investigating ocular AAV gene treatments.
• An advanced macrophage cell therapy system is being developed by SIRPant Immunotherapeutics, a preclinical immuno-oncology business, for the cure of different types of solid tumors by facilitating patient immune response activation.
• A preclinical biotechnology startup called Stream Biomedical is dedicated to using its modified perlecan domain V to create ground-breaking cures for severe neurodegenerative diseases like stroke.
• Lead prospects for Taysha’s large AAV gene therapy pipeline include treatments for the conditions GM2 gangliosidosis, Rett syndrome, including CLN1.
• A preclinical biotechnology startup called Trefoil Therapeutics is working to create 1st pharmaceutical treatments for significant corneal endothelium illnesses and epithelial abnormalities using its altered fibroblast growth factor-1 protein (eFGF-1) technology company.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors’ new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*

Insider trading is a topic of intense discussion among academics and industry experts in the financial sector regarding whether it benefits or harms markets. Insider trading is defined as the acquisition or sale of securities by a person who has access to substantial, non-public information.

Insider trading is not just a problem for corporate executives, board members, and workers. If they obtain access to private information, outside investors, brokers, and fund managers may potentially break the law while engaging in insider trading.

One defense of insider trading is that it permits nonpublic knowledge, not simply publicly available information, to be reflected in the price of an asset. Insider trading is opposed by those who believe it would improve market efficiency.

The trend of the price, for instance, informs other shareholders as insiders and other parties with insider information buy or sell a company’s shares. Prospective investors and existing investors can both buy and sell based on price changes. Current investors might sell for more money, while potential investors could buy at greater prices.

Postponing the Inevitable?

Another argument in support of the practice is that prohibiting it would just postpone the inevitable and result in investor mistakes. The price of a security will change based on relevant facts.

Let’s say an insider hears positive news about a business but is unable to purchase its stock. Then, a price increase is avoided from occurring for those who sell during the interval between when the insider discovers the news and when it becomes known to the general public. Errors may occur if investors are denied easy access to information or obtain it inadvertently through price changes. If the data had been ready earlier, they might have traded a stock they otherwise would not have, such as buying or selling it.

Insider trading laws can put innocent people in jail, especially if they are strictly enforced. Due to the difficulty in determining what is and is not legal as rules grow increasingly complex, participants sometimes inadvertently break the law.

For instance, a person having access to sensitive information can unintentionally reveal it to a visited relative while on the phone. If the relative uses that knowledge and is detected, the person who unintentionally revealed it might also face prison time. Risks of this nature cause people to become so afraid that they look for work elsewhere.

The claim that insider trading is not significant enough to warrant prosecution is another justification for permitting it. To execute the laws against insider trading, the government must use its little resources to apprehend peaceful traders. Since the government can divert funds from instances of blatant theft, violent assault, and sometimes even murder, looking after insider trading has an opportunity cost.

Defenses of Insider Trading

One defense against insider trading is that the public might believe that markets are unfair if a small number of people trade on important nonpublic information. As a result, regular investors can lose faith in the financial system and avoid participating in rigged markets.

Insiders with access to secret information might be able to profit from gains and prevent losses. As a result, the inherent risk that investors who lack the information disclose while making investments is effectively eliminated. Businesses would have more trouble raising money if the public loses faith in the markets. There may not be many outsiders remaining in the end. Insider trading might thus be completely eliminated.

Another defense against insider trading is that it deprives investors of getting the full value for their assets when they don’t have access to inside information. Before insider trading took place, if nonpublic knowledge got widely known, the markets would incorporate it, leading to appropriately valued stocks.

Let’s say a pharmaceutical company announces in a week that Phase 3 trials of a new vaccine were successful. An investor then has the chance to take advantage of that nonpublic information.

Whenever the information was made available to the public, one such investor might buy shares of the pharmaceutical company. By purchasing call options, the investor could stand to gain greatly from a price increase that occurs after the information is made public. Without knowing that the Phase 3 trials were successful, the investor who traded the options most likely might not have performed so.

Whether Insider Trading Is Legal?

Court judgments of other statutes, such as the Securities Exchange Act of 1934, made some forms of insider trading illegal. The Securities and Exchange Commission (SEC) must be informed of any purchasing or selling action by directors of a firm in order for insider trading to be considered legal.

Members of Congress were exempt from insider trading rules for a very long time. Throughout most of the financial crisis in 2008, some parliamentarians sought to benefit from significant private data, which brought this issue to the public’s notice. To address this issue, the STOCK Act was overwhelmingly approved by Congress and became law in 2012 under President Barack Obama.

Insider Trading Examples

Michael Milken, referred to throughout the 1980s as the “Junk Bond King,” is an example of insider trading. During his time at the now-defunct investment bank Drexel Burnham Lambert, Milken became renowned for trading trash bonds and contributed to the growth of the market for sub-investment grade debt.

Milken was charged with exploiting secret information about junk bond agreements that investors and businesses were orchestrating to acquire rival businesses. He was accused of using the rise in the takeover targets’ stock values following the announcement of the deal by using the information to buy shares in them.

Imagine that the shareholders who sold Milken their stock knew that bond arrangements were being set up to pay for the acquisition of those businesses. They probably would have kept their shares in order to benefit from the increase. Instead, only those in Milken’s position might profit from the non-public information. In the end, Milken admitted to engaging in securities fraud, was sentenced to two years in prison, was fined $600 million, and was permanently barred from the securities industry.

The Verdict

Insider trading has both supporters and detractors. Opponents of insider trading contend that it tilts the playing field in favor of those who possess confidential information. Insider trading proponents contend that doing so reduces risks and improves market efficiency.

Regardless of one’s position, Insider Trading is currently prohibited and is subject to harsh penalties, including fines and jail time. If you also want to start your insider trading journey, you can begin with the Spiking Race to 100 where you will find top insider secrets for great winnings.

• Li Ka-shing, sometimes known as Superman, is regarded to be one of the most powerful businessmen in Asia.
• In May 2018, Li stepped down as chairman of CK Hutchison Holdings and CK Asset Holdings, however he is still a senior advisor.
• Li made light of the fact that he had been “working for a long period of time, too long” when he announced his retirement.
• The group, which employs more than 300,000 people and conducts business in more than 50 countries, is now led by his son Victor.
• With $6,500 in savings and loans from family, Li founded Cheung Kong Plastics, which bears the Yangtze River’s name, in 1950 when he was just 21 years old.
• Over 80% of the $3.3 billion in donations made by his Li Ka Shing Foundation went to Greater China.

Global Achievements

1. On Forbes Lists – Got 37th rank in Billionaires list (2022)
2. Got 1st Rank in Hong Kong’s 50 Richest (2022)
3. Managed 46th Rank in Powerful People (2018)

Li Ka-shing-backed fund Trusting Southeast Asia For Gold Returns

Chau, a co-founder of Horizons Ventures, also aims to ‘Women-centric’ companies in Japan

The private investment wing of Hong Kong billionaire Li Ka-shing, Horizons Ventures, is expanding its partnerships in Southeast Asia and focusing on “women-centric” projects in Japan in order to diversify its U.S.-focused holdings.

The organization has approximately 140 active investments throughout 17 nations, with the United States accounting for about one-third of those. However, the Hong Kong-based company has strengthened its position in Southeast Asia by opening an office in Singapore early this year.

“We’ve established a Southeast Asia cluster with a different goal in mind: to test if we can quickly integrate a tonne of new technology into the established manufacturers”, informed Solina Chau, Li’s longstanding business partner and the co-founder of the firm, in a recent conversation with Nikkei Asia.

According to financial news website DealStreetAsia, although Southeast Asian entrepreneurs obtained at least $25.7 billion in funding last year—nearly three times that of 2020—deal activity reported a steep fall in the second quarter of this year as a result of deteriorating macroeconomic conditions.

Some wealthy businesses have grabbed the opportunity to increase their investments in Southeast Asian emerging economies in the face of these global headwinds.

Sequoia Capital reported in June that it had raised $2.85 billion for projects in Southeast Asia and India.

The speech recognition programme Siri and the videoconferencing startup Zoom were also profitable bets for the already 94-year-old Li, who co-founded Horizons in 2005.

Chau, who oversees the organization and is launching a new business plan, is now in the spotlight.

Twelve of Horizons’ twenty-two ventures are in Australia, five are in Indonesia, and seven are in India. The business’s first office outside of Hong Kong, which just launched in Singapore, aims to aid the expansion of its portfolio firms in Southeast Asia.

However, the expansion has fueled concerns that the business would relocate entirely as Hong Kong experiences a talent and capital migration amid stringent COVID-19 regulations and 2 years ever since the implementation of a national security law enforced by Beijing.

Chau rejected the notion that Horizons wanted to leave tax-friendly Hong Kong.

“Our business is not big. We have individuals in their 20s. How many people will I be moving?” When questioned about the rumors, Chau responded. I was born and raised in Hong Kong, and as long as the tax system doesn’t change, it’s still a fascinating place to be.

Along with geographic diversification, Horizons is also looking to make new investments in initiatives that focus on the environment and women.

“Do you have scientific advancements that could result in formula milk that is superior to breast milk? What benefits both the globe and women more?” said Chau. It is what we are focusing on and clustering around.

Japan ranked first for gender equity in academic achievement among the 146 nations included in the most recent World Economic Forum gender gap assessment. But it severely dropped to position 121 in the sub index of economic security and engagement, instead of Congo.

The female entrepreneur of a Japanese firm in Horizons’ portfolio was cited by Chau as saying, “There’s a lot of unspoken racism in Japan towards women founders.” In Japan, we have an intriguing investment strategy that is entirely centered on women.

With partnerships in 3 female-founded companies, including the space startup ALE, the dermatology research company Nanoegg, and the Japanese venture capital firm MPower Partners, Japan is an emerging standout in Horizons’ portfolio.

With a goal of tripling the amount of startups in Japan in 5 years, the government is taking steps to support the startup environment in the nation by creating a ministerial position to supervise innovation initiatives.

Despite the government potentially having a sizable national debt, the aspirational plan involves investing public money in potential businesses.

The ministerial appointment, according to Chau, “is another enormous bureaucracy to tackle a big problem.” “cheque is crucial, but your firms also have funds,”

To jumpstart the sector, she argued, Tokyo should gather up academics, innovators, and large corporations.

According to Chau, the government’s effort and commitment are just as significant as its funding. “Japan ought to be a powerhouse in the world of inventive startups. Deep science is extremely prevalent, especially in Europe.”

Latest Insider Details

Singapore Fund Purchases Hong Kong Properties From Billionaire Li Ka-CK Shing’s Property $2.6 5 billion

Li Ka-shing, the richest man in Hong Kong, has decided to sell a few of his real estate properties to CK Asset Holdings for HK$20.8 billion ($2.65 billion).

On Wednesday, ORIC-Borrett and CK Asset reached an agreement to purchase CK Asset’s sole share in Aim Clever Holdings. Aim Clever Holdings is a division of the development company and is in charge of 21 Borrett Road’s 152 housing properties, 242 residential parking areas, and 31 motorbike parking areas. By March 2025, the transaction is anticipated to be finished.

In a late-Wednesday filing with the Hong Kong Stock Exchange, ORIC-Borrett is controlled by a sub-fund of the fund LC Vision Capital VCC of the Singapore asset management firm Sino Suisse.

The transaction would net CK Asset a profit of HK$6.3 billion, which will be put to use for basic working capital needs.

This is CK Asset’s second real estate deal of the year. The developer’s subsidiary CK Steel Holdings managed to sell its shares in Blue Button Holdco 5 Broadgate (Jersey), a business that holds investment buildings in London, for £729.2 million ($788 million) in March.

Based on a Bloomberg News story, the 21 Borrett Road property broke a record last year by selling the far more expensive property in Asia for HK$459 million, or HK$136,000 per square foot. HK$640 million, or HK$140,800 per square foot, was paid by Wharf Holdings and Nan Fung Development for a residence on the Peak, breaking the previous record nine months later.

Spiking Race to 100

We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors’ new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!

Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!

*